Revolutionizing Cancer Research: Meet Dr. Juliet Daniel, the Trailblazing Black Scientist Making a Difference in the Lives of Triple Negative Breast Cancer (TNBC) Patients
Revolutionizing Cancer Research: Meet Dr. Juliet Daniel, the Trailblazing Black Scientist Making a Difference in the Lives of Triple Negative Breast Cancer (TNBC) Patients Written by Tom Raycove, CEO Disrupted Logic Interactive Inc. Celebrating Black History Month, we shine a spotlight on Dr. Juliet Daniel, a trailblazer in the field of cancer research. Driven by […]
Breaking Barriers – Past and Current: Celebrating the Legacy of Dr. Clarice Reid, Pioneer in Sickle Cell Research, Biomark Diagnostics
Breaking Barriers Past: Celebrating the Legacy of Dr. Clarice Reid, Pioneer in Sickle Cell Research Current: BioMark Diagnostics Inc. Pioneering Early Stage Cancer Detection Written by Tom Raycove, CEO Disrupted Logic Interactive Inc. Dr. Clarice Reid: Pioneering Work in the Field of Sickle Cell Disease Dr. Clarice Reid was a trailblazer in the field of […]
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that […]
Form 7 Monthly Progress Report January 1 2023
Form 7 Monthly Progress Report February 1 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 February 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Biomark Announces Update From Oongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test As It Prepares For Commercial Launch
BIOMARK ANNOUNCES UPDATE FROM ONGOING CLINICAL TRIAL USING ITS LUNG CANCER LIQUID BIOSPY TEST AS IT PREPARES FOR COMMERCIAL LAUNCH Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and […]
Form 7 Monthly Progress Report December 1 2022
Form 7 Monthly Progress Report November 1 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 January 4, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
Form 7 Monthly Progress Report November 1 2022
Form 7 Monthly Progress Report November 1, 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 December 6, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the […]
Form 7 Monthly Progress Report October 1 2022
Form 7 Monthly Progress Report November 1, 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 November 1, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended […]
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today […]
